Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma-Reference-Cited by-同舟云学术

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

Published:2015-03-18 Issue:279 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Hu-Lieskovan Siwen¹,Mok Stephen¹,Homet Moreno Blanca¹²,Tsoi Jennifer³⁴,Robert Lidia¹,Goedert Lucas¹,Pinheiro Elaine M.⁵,Koya Richard C.¹,Graeber Thomas G.³⁴⁶,Comin-Anduix Begoña⁶⁷,Ribas Antoni¹⁴⁶⁷

Affiliation:

1. Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

2. Division of Translational Oncology, Carlos III Health Institute, Madrid 28029, Spain.

3. Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA.

4. Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.

5. Merck Research Laboratories, Boston, MA 02115, USA.

6. Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.

7. Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.

Abstract

MEK inhibition enhanced the antitumor activity of combined BRAF inhibition and immunotherapy.

Funder

NIH

American Cancer Society Research Scholar Award

CONCERN Foundation

Melanoma Research Alliance Established Investigator Award

National Center for Advancing Translational Sciences

ASCO (American Society of Clinical Oncology) Young Investigator Award

Tower Foundation Research

Dr. Robert Vigen Memorial Fund

Ressler Family Foundation

Wesley Coyle Memorial Fund

Garcia-Corsini Family Fund

Spanish Society of Medical Oncology (SEOM)

National Cancer Institute/NIH

NIH Ruth L. Kirschstein Institutional National Research Service Award

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference43 articles.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

3. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

4. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

5. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Cited by 493 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resistance;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Colorectal Cancer with BRAF V600E Mutation: Trends in Immune Checkpoint Inhibitor Treatment;Critical Reviews in Oncology/Hematology;2024-09

3. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature;Drugs in R&D;2024-08-23

4. An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls;Clinical and Experimental Medicine;2024-07-13

5. PIKfyve, expressed by CD11c-positive cells, controls tumor immunity;Nature Communications;2024-06-28